Key Market Drivers, Trends, and Forecast for the Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Industry
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Heading Into 2029?
In recent times, there has been a quick surge in the size of the primary progressive multiple sclerosis (ppms) treatment market. It is forecasted to expand from $1.02 billion in 2024 to $1.16 billion in 2025, with a compound annual growth rate (CAGR) of 13.7%. Factors such as a higher prevalence of PPMS in the older population, escalated awareness and comprehension of PPMS among patients and healthcare practitioners, increased investment in R&D for PPMS therapies, a growing preference for disease-modifying therapies (DMTs), and wider government initiatives and financial support for innovative PPMS treatments contribute to the growth experienced during this historical period.
In the upcoming years, it is predicted that the primary progressive multiple sclerosis (ppms) treatment market will witness substantial growth, reaching a value of $1.92 billion in 2029, at a 13.5% compound annual growth rate (CAGR). This growth can be tied to various elements such as the rising number of clinical trials for new PPMS drugs, advancements in diagnosis methods, the escalating demand for personalized and targeted medical treatments, increased healthcare infrastructure and an uptick in collaborations and partnerships between pharmaceutical companies. Key trends impacting this predicted growth include advancements in therapies that slow PPMS progression, the integration of research on biomarkers for tailored treatment strategies, technology-enabled advancements in MRI and other diagnostic imaging techniques, headway in the study of neuroprotective and remyelination drugs, and advancements in using genetic and molecular profiling for patient categorization.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24670&type=smp
Which Factors Are Pushing The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Forward?
Anticipated growth in the primary progressive multiple sclerosis (PPMS) treatment market can be attributed to an increasing demand for effective therapeutic interventions. Such treatments are instrumental in minimizing symptoms, enhancing patient prognosis, or in some cases even curing the disorder or disease completely. This increasing demand is usually triggered by a surge in chronic and intricate health conditions which necessitate long-term management along with advanced therapeutic measures for improving the patients’ quality of life and overall condition. These effective treatments act by tackling inflammation and maintaining neurological functions, thereby delaying the progression of primary progressive multiple sclerosis (PPMS). This not only improves the quality of life over time, but it also slows down disability accumulation while bolstering the patients’ capacity to handle everyday tasks more independently and stably. As an example, in January 2024, the American Society of Gene & Cell Therapy, a US-based gene and cell therapy organization, reported that the number of gene therapies in Phase III clinical trials rose to 33 from 30 in 2023 – a 10% increase compared to 2022, and was the first quarter-on-quarter rise since Q3 2022. As such, it’s clear that the mounting demand for effective treatments is fueling the growth of the primary progressive multiple sclerosis (PPMS) treatment market.
Which Segment Held The Largest Share In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market In 2025?
The primary progressive multiple sclerosis (PPMS) treatment market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunosuppressants, Corticosteroids, Other Drug Types
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Ocrelizumab, Rituximab, Ofatumumab, Ublituximab
2) By Immunosuppressants: Methotrexate, Azathioprine, Mycophenolate Mofetil, Cyclophosphamide
3) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone, Hydrocortisone
4) By Other Drug Types: Biotin, Ibudilast, Laquinimod, Idebenone
How Are Key Trends Driving Expansion In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Industry?
Major corporations active in the market for primary progressive multiple sclerosis (PPMS) treatment are prioritizing the invention of novel formulations, such as monoclonal antibody drugs, to improve multiple sclerosis treatment. Monoclonal antibody medications target specific inflammatory-causing immune cells or proteins and diminish damage to the nervous system, thereby minimizing disease activity and slowing symptom progression. For example, in February 2024, Ocrevus (ocrelizumab), a monoclonal antibody medication for MS, was launched in India by Roche Pharma India, a pharmaceutical company based in the country. Ocrevus holds the distinction of being the only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and PPMS in India. The drug operates by targeting CD20-positive B cells, which are immune cells involved in the irregular immune reaction observed in MS. Administered through a bi-annual intravenous infusion lasting only two hours, it offers a more flexible and effective solution for patients.
Which Organizations Are Driving Progress In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Industry?
Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are F. Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, Brainstorm Cell Therapeutics Inc.
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Industry?
North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (PPMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24670&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
